Resources

Explore our extensive resources to uncover more about RCA's expertise in life sciences consulting.

Content Type

Segment

Industries

Published Articles

Quality Considerations for Using AI in Bio/Pharma

In the second episode of the Ask the Expert video series, Susan J. Schneipp, distinguished fellow at Regulatory Compliance Associates, and Siegfried Schmitt, vice-president, Technical, at Parexel, discuss the quality...
Read More about Quality Considerations for Using AI in Bio/Pharma

Published Articles

The Future of Biotech Quality

Experts share insights on what the future may hold regarding biotech quality, regulatory requirements and quality standards for biotechnology industry. The biotech industry has experienced significant growth in recent years....
Read More about The Future of Biotech Quality

Published Articles

Remediation Costs of Non-Compliance

Costs of Non-Compliance An effective corrective and preventive action (CAPA) program should do more than address an FDA observation. It should identify the root cause of a nonconformance, correct the...
Read More about Remediation Costs of Non-Compliance

Published Articles

Quality Risk Management Plan

A well-written and well-implemented quality risk management plan is an integral element of an effective quality system. During the development of your total quality strategy, the bottom line is that...
Read More about Quality Risk Management Plan

Published Articles

Compendial Requirements

Maintaining compliance to compendial requirements should be straightforward, says Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates. Q: Do I need to comply with all aspects of the various...
Read More about Compendial Requirements

Published Articles

FDA Inspections: Hope is Not a Strategy

Subject matter experts from Regulatory Compliance Associates® Inc. discuss how too many organizations scramble when an FDA inspection occurs because they fail to be adequately prepared. True inspection preparedness, however,...
Read More about FDA Inspections: Hope is Not a Strategy